Biocon

Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
Pharma Voice
Tue, 04/9/24 - 05:45 pm
biosimilars
Biocon
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
Thu, 07/27/23 - 10:25 am
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
7 companies are rolling out Humira biosimilars
Drugstore News
Wed, 07/12/23 - 09:44 am
AbbVie
Humira
biosimilars
Boehringer Ingelheim
Organon
Samsung Bioepsis
Sandoz
Fresenius Kabi
Celltrion
Coherus Biosciences
Biocon
FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks
Endpoints
Mon, 02/13/23 - 10:02 pm
FDA
Biocon
Viatris
Avastin
biosimilars
drug manufacturing
Takeover-driven resurgence fails to materialize for biotech
EP Vantage
Thu, 04/14/22 - 10:41 am
M&A
AbbVie
Biocon
Biogen
Biohaven
GSK
Halozyme Therapeutics
Samsung Bioepis
UCB
Viatris
Biocon buys Viatris biosimilars for $3.3bn, eyes IPO
Pharmaforum
Mon, 02/28/22 - 09:20 am
Biocon
India
Viatris
Mylan
biosimilars
M&A
Viatris launched two versions of its interchangeable insulin biosimilar. Why?
Fierce Pharma
Tue, 11/16/21 - 10:29 pm
Biocon
Viatris
Semglee
insulin
biosimilars
diabetes
Sanofi
Lantus
How This Historic FDA Approval Benefits Viatris
Motley Fool
Wed, 08/4/21 - 10:57 am
Viatris
Biocon
FDA
Semglee
biosimilars
insulin
diabetes
interchangeable biosimilars
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Center for Biosimilars
Tue, 09/1/20 - 10:44 am
Biocon
Mylan
Semglee
generics
insulin
diabetes
biosimilars
Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
Motley Fool
Fri, 06/12/20 - 08:03 pm
FDA
Mylan
Biocon
Semglee
Sanofi
insulin
Lantus
diabetes
Biocon insulin operation gets FDA nod, paving way for approval of Lantus knockoff
Fierce Pharma
Thu, 04/2/20 - 11:58 pm
Biocon
insulin
diabetes
Lantus
Mylan
drug manufacturing
Mylan's Lantus copy derailed in U.S. again by manufacturing ills
Fierce Pharma
Tue, 09/3/19 - 10:24 am
Mylan
Lantus
generics
Biocon
drug manufacturing
diabetes
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
Fierce Pharma
Mon, 07/8/19 - 10:18 pm
FDA
Biocon
Mylan
Sanofi
Lantus
insulin
drug manufacturing
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Fierce Pharma
Fri, 10/12/18 - 12:47 pm
Merck
Samsung Bioepis
Lantus
insulin
diabetes
biosimilars
Mylan Labs
Biocon
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
CP Wire
Thu, 05/3/18 - 11:11 pm
Coherus Biosciences
Neulasta
CHS-1701
Mylan
Biocon
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
Thu, 05/3/18 - 02:45 pm
Coherus Biosciences
Neulasta
CHS-1701
Mylan
Biocon
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Endpoints
Thu, 01/18/18 - 10:35 pm
Novartis
Biocon
drug development
biosimilars
FDA Approves Eighth Biosimilar, First for Cancer Drug Herceptin
RAPS.org
Sat, 12/2/17 - 11:20 am
FDA
biosimilars
Herceptin
Ogivri
Mylan Labs
Biocon
Biocon and Mylan say their plant is good to go as FDA decision nears for their Herceptin copy
Fierce Pharma
Tue, 11/21/17 - 11:42 am
Biocon
Mylan Labs
FDA
Herceptin
drug manufacturing
biologics
India
Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL
Fierce Pharma
Tue, 10/10/17 - 10:18 am
Mylan Labs
Biocon
Amgen
Neulasta
CRL
FDA
biosimilars

Pages